Luminal androgen receptor role and pathological complete response rate to neoadjuvant chemotherapy in triple negative breast cancer

被引：0

作者：

Chica-Parrado, M. R. ^{[1
]}

Santonja, A. ^{[1
]}

Lluch-Hernandez, A. ^{[2
]}

Albanell, J. ^{[3
]}

Sanchez-Munoz, A. ^{[1
]}

Chacon, I. ^{[4
]}

Calvo, L. ^{[5
]}

Sanchez-Rovira, P. ^{[6
]}

De la Haba, J. ^{[7
]}

Vicioso, L. ^{[1
]}

Martin, M. ^{[4
]}

Plazaola, A. ^{[8
]}

Prat, A. ^{[4
]}

Ribelles, N. ^{[1
]}

Sanchez-Arago, M. ^{[4
]}

Jerez, J. M. ^{[1
]}

Escudero, M. J. ^{[4
]}

Caballero, R. ^{[4
]}

Carrasco, E. ^{[7
]}

Alba Conejo, E. ^{[1
]}

机构：

[1] Biomed Res Inst Malaga IBIMA, Translat Oncol, Malaga, Spain

[2] Hosp Clin Univ Valencia, Serv Hematol & Oncol Med, Valencia, Spain

[3] Inst Hosp del Mar Invest Med IMIM, Canc Res Program, Barcelona, Spain

[4] GEICAM Spanish Breast Canc Res Grp, Translat Res, Madrid, Spain

[5] Univ Hosp Complex A Coruna, Med Oncol, La Coruna, Spain

[6] Univ Jaen, Med Oncol, Complejo Hosp, Jaen, Spain

[7] GEICAM Spanish Breast Canc Res Grp, Madrid, Spain

[8] Onkol Kutxaren Inst Onkol, Dept Med Oncol, San Sebastian, Spain

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

10.1093/annonc/mdw364.43

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

187P

引用

页数：1

共 50 条

[1] Bevacizumab in Neoadjuvant Chemotherapy Increases the Pathological Complete Response Rate in Patients With Triple-Negative Breast Cancer
Barton, Mary Kay
[J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2014, 64 (03) : 155 - 156
[2] Clinical predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer
Nakashoji, Ayako
Matsui, Akira
Nagayama, Aiko
Iwata, Yuko
Sasahara, Manami
Murata, Yuya
[J]. ONCOLOGY LETTERS, 2017, 14 (04) : 4135 - 4141
[3] Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer – single hospital experience
Elina Sivina
Lubova Blumberga
Gunta Purkalne
Arvids Irmejs
[J]. Hereditary Cancer in Clinical Practice, 21
[4] Pathological complete response to neoadjuvant chemotherapy in triple negative breast cancer - single hospital experience
Sivina, Elina
Blumberga, Lubova
Purkalne, Gunta
Irmejs, Arvids
[J]. HEREDITARY CANCER IN CLINICAL PRACTICE, 2023, 21 (01)
[5] Improving pathological complete response in luminal breast cancer after neoadjuvant chemotherapy
Cudos, Ariadna Gasol
Murillo, Serafin Morales
Galindo, Alvaro Rodriguez
Subirats, Ona Pallise
Olive, Jordi Mele
Morales, Carles Canosa
Villellas, Felip Vilardell
Guzman, Douglas Rene Sanchez
Rodriguez, Joel Veas
[J]. CANCER RESEARCH, 2022, 82 (04)
[6] Pathological complete response (pCR) after neoadjuvant chemotherapy in luminal breast cancer
Cordoba Ortega, J. F.
Gasol Cudos, A.
Morales Murillo, S.
Vilardell Villellas, F.
Siso Raber, C.
Canosa Morales, C.
Salud Salvia, A.
[J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S313 - S313
[7] Androgen Receptor Status and Prediction of Neoadjuvant Chemotherapy Response in Triple-Negative Breast Cancer
Stoos, Catherine
Huggins-Puhalla, Shannon
Dabbs, David
Bhargava, Rohit
[J]. LABORATORY INVESTIGATION, 2016, 96 : 74A - 74A
[8] Androgen Receptor Status and Prediction of Neoadjuvant Chemotherapy Response in Triple-Negative Breast Cancer
Stoos, Catherine
Huggins-Puhalla, Shannon
Dabbs, David
Bhargava, Rohit
[J]. MODERN PATHOLOGY, 2016, 29 : 74A - 74A
[9] The role of glucocorticoid receptor (GR) expression in predicting pathological complete response (pCR) to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC)
Saha, P.
Turk, A.
Lurain, K.
Baker, G.
Conzen, S.
Nanda, R.
[J]. CANCER RESEARCH, 2016, 76
[10] A preliminary study on predicting pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer
Chen, Xi
Zhou, Zhiguo
[J]. CANCER RESEARCH, 2024, 84 (03)

← 1 2 3 4 5 →